Download PDF
Geburtshilfe Frauenheilkd 2005; 65(12): 1130-1140
DOI: 10.1055/s-2005-872918
Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Mammakarzinom und Viren

Breast Carcinoma and VirusesM. A. Stoff-Khalili1 , 2 , D. T. Curiel2 , P. Dall1
  • 1Frauenklinik der Heinrich-Heine-Universität, Düsseldorf
  • 2Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL, USA
Further Information

Publication History

Eingang Manuskript: 8.7.2005 Eingang revidiertes Manuskript: 8.9.2005

Akzeptiert: 21.9.2005

Publication Date:
18 January 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Auf der Suche nach neuen Therapieformen zur Behandlung des metastasierenden Mammakarzinoms stellt die Virotherapie eine Erfolg versprechende Methode dar. In der folgenden Übersicht werden das Konzept, Strategien und der gegenwärtige Stand der Virotherapie beim Mammakarzinom dargelegt. Ferner wird die virale Ätiologie des Mammakarzinoms evaluiert und diskutiert.

Abstract

In the search for new forms of therapy to treat metastasizing breast carcinoma virotherapy appears to offer some promise. In the following, the concept, strategies and current state of knowledge on virotherapy for the treatment of breast carcinoma is presented. The viral etiology of breast carcinoma is evaluated and discussed.

Schlüsselwörter

Mammakarzinom - Viren - Virotherapie - Gentherapie - CRAds - Adenovirus - Maus-Mamma-Tumor Virus (MMTV)

Key words

Breast carcinoma - virotherapy - gene therapy - CRAds - adenovirus - mouse-mammary-tumor virus (MMTV)

Literatur

  • 1 Jemal A, Clegg L X, Ward E, Ries L A, Wu X, Jamison P M, Wingo P A, Howe H L, Anderson R N, Edwards B K. Annual report to the nation on the status of cancer, 1975 - 2001, with a special feature regarding survival.  Cancer. 2004;  101 3-27
    CrossrefPubMedGoogle Scholar
  • 2 Bilbao R, Bustos M, Alzuguren P, Pajares M J, Drozdzik M, Qian C, Prieto J. A blood-tumor barrier limits gene transfer to experimental liver cancer: The effect of vasoactive compounds.  Gene Ther. 2000;  7 1824-1832
    CrossrefPubMedGoogle Scholar
  • 3 Stoff-Khalili M A, Dall P, Curiel D T. From gene therapy to virotherapy for ovarian cancer.  Minerva Ginecol. 2004;  56 503-514
    PubMedGoogle Scholar
  • 4 Alemany R, Balague C, Curiel D T. Replicative adenoviruses for cancer therapy.  Nat Biotechnol. 2000;  18 723-727
    PubMedGoogle Scholar
  • 5 Nettelbeck D M. Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis.  Anticancer Drugs. 2003;  14 577-584
    PubMedGoogle Scholar
  • 6 Kruyt F A, Curiel D T. Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis.  Hum Gene Ther. 2002;  13 485-495
    CrossrefPubMedGoogle Scholar
  • 7 Bauerschmitz G J, Hemminki A, Curiel D T, Dall P. Tumour-dependent replicating adenoviruses in the treatment of carcinomas.  Zentralbl Gynakol. 2004;  126 280-281
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Kirn D, Martuza R L, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.  Nat Med. 2001;  7 781-787
    CrossrefPubMedGoogle Scholar
  • 9 Kirn D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer.  Oncogene. 2000;  19 6660-6669
    CrossrefPubMedGoogle Scholar
  • 10 Yang W Q, Senger D L, Lun X Q, Muzik H, Shi Z Q, Dyck R H, Norman K, Brasher P M, Rewcastle N B, George D, Stewart D, Lee P W, Forsyth P A. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.  Gene Ther. 2004;  11 1579-1589
    CrossrefPubMedGoogle Scholar
  • 11 Norman K L, Coffey M C, Hirasawa K, Demetrick D J, Nishikawa S G, DiFrancesco L M, Strong J E, Lee P W. Reovirus oncolysis of human breast cancer.  Hum Gene Ther. 2002;  13 641-652
    CrossrefPubMedGoogle Scholar
  • 12 Ebert O, Harbaran S, Shinozaki K, Woo S L. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.  Cancer Gene Ther. 2005;  12 350-358
    CrossrefPubMedGoogle Scholar
  • 13 Stojdl D F, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell J C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.  Nat Med. 2000;  6 821-825
    CrossrefPubMedGoogle Scholar
  • 14 Mundschau L J, Faller D V. Endogenous inhibitors of the dsRNA-dependent eIF‐2 alpha protein kinase PKR in normal and ras-transformed cells.  Biochimie. 1994;  76 792-800
    CrossrefPubMedGoogle Scholar
  • 15 Stojdl D F, Lichty B D, tenOever B R, Paterson J M, Power A T, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown E G, Durbin R K, Durbin J E, Hiscott J, Bell J C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.  Cancer Cell. 2003;  4 263-275
    CrossrefPubMedGoogle Scholar
  • 16 Fabra A, Parada C, Vinyals A, Martin Duque P, Fernandez V, Sanchez-Prieto R, Ramon y Cajal S. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts.  Gene Ther. 2001;  8 1627-1634
    CrossrefPubMedGoogle Scholar
  • 17 Coukos G, Makrigiannakis A, Kang E H, Rubin S C, Albelda S M, Molnar-Kimber K L. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p 53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.  Clin Cancer Res. 2000;  6 3342-3353
    PubMedGoogle Scholar
  • 18 Todo T, Martuza R L, Rabkin S D, Johnson P A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.  Proc Natl Acad Sci USA. 2001;  98 6396-6401
    CrossrefPubMedGoogle Scholar
  • 19 Liu R, Varghese S, Rabkin S D. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.  Cancer Res. 2005;  65 1532-1540
    CrossrefPubMedGoogle Scholar
  • 20 Liu R, Martuza R L, Rabkin S D. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.  Gene Ther. 2005;  12 647-654
    CrossrefPubMedGoogle Scholar
  • 21 Glasgow J N, Bauerschmitz G J, Curiel D T, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications.  Curr Gene Ther. 2004;  4 1-14
    CrossrefPubMedGoogle Scholar
  • 22 Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke M F. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.  Hum Gene Ther. 2002;  13 1737-1750
    CrossrefPubMedGoogle Scholar
  • 23 Yu L, Yamamoto N, Kadomatsu K, Muramatsu T, Matsubara S, Sakiyama S, Tagawa M. Midkine promoter can mediate transcriptional activation of a fused suicide gene in a broader range of human breast cancer compared with c-erbB‐2 promoter.  Oncology. 2004;  66 143-149
    CrossrefPubMedGoogle Scholar
  • 24 Zhang L, Akbulut H, Tang Y, Peng X, Pizzorno G, Sapi E, Manegold S, Deisseroth A. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma.  Mol Ther. 2002;  6 386-393
    CrossrefPubMedGoogle Scholar
  • 25 Zhu Z B, Makhija S K, Lu B, Wang M, Kaliberova L, Liu B, Rivera A A, Nettelbeck D M, Mahasreshti P J, Leath C A, Barker S, Yamaoto M, Li F, Alvarez R D, Curiel D T. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.  Cancer Gene Ther. 2004;  11 256-262
    CrossrefPubMedGoogle Scholar
  • 26 Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.  Cancer Gene Ther. 2003;  10 388-395
    CrossrefPubMedGoogle Scholar
  • 27 Godbey W T, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery.  Gene Ther. 2003;  10 1519-1527
    CrossrefPubMedGoogle Scholar
  • 28 Lu B, Makhija S K, Nettelbeck D M, Rivera A A, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma H J, Alvarez R D, Curiel D T, Zhu Z B. Evaluation of tumor-specific promoter activities in melanoma.  Gene Ther. 2005;  12 330-338
    CrossrefPubMedGoogle Scholar
  • 29 McLaughlin P M, Trzpis M, Kroesen B J, Helfrich W, Terpstra P, Dokter W H, Ruiters M H, de Leij L F, Harmsen M C. Use of the EGP‐2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.  Cancer Gene Ther. 2004;  11 603-612
    CrossrefPubMedGoogle Scholar
  • 30 McLaughlin P M, Harmsen M C, Dokter W H, Kroesen B J, van der Molen H, Brinker M G, Hollema H, Ruiters M H, Buys C H, de Leij L F. The epithelial glycoprotein 2 (EGP‐2) promoter-driven epithelial-specific expression of EGP‐2 in transgenic mice: A new model to study carcinoma-directed immunotherapy.  Cancer Res. 2001;  61 4105-4111
    PubMedGoogle Scholar
  • 31 Zabner J, Freimuth P, Puga A, Fabrega A, Welsh M J. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection.  J Clin Invest. 1997;  100 1144-1149
    PubMedGoogle Scholar
  • 32 Okegawa T, Li Y, Pong R C, Bergelson J M, Zhou J, Hsieh J T. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.  Cancer Res. 2000;  60 5031-5036
    PubMedGoogle Scholar
  • 33 Shayakhmetov D M, Li Z Y, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.  Cancer Res. 2002;  62 1063-1068
    PubMedGoogle Scholar
  • 34 Li Y, Pong R C, Bergelson J M, Hall M C, Sagalowsky A I, Tseng C P, Wang Z, Hsieh J T. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy.  Cancer Res. 1999;  59 325-330
    PubMedGoogle Scholar
  • 35 Seidman M A, Hogan S M, Wendland R L, Worgall S, Crystal R G, Leopold P L. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle.  Mol Ther. 2001;  4 13-21
    CrossrefPubMedGoogle Scholar
  • 36 Okegawa T, Pong R C, Li Y, Bergelson J M, Sagalowsky A I, Hsieh J T. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: A functional analysis of car protein structure.  Cancer Res. 2001;  61 6592-6600
    PubMedGoogle Scholar
  • 37 Walters R W, Freimuth P, Moninger T O, Ganske I, Zabner J, Welsh M J. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape.  Cell. 2002;  110 789-799
    CrossrefPubMedGoogle Scholar
  • 38 Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel D T. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency.  Hum Gene Ther. 2002;  13 1647-1653
    CrossrefPubMedGoogle Scholar
  • 39 Stoff-Khalili M A, Stoff A, Rivera A A, Mathis J M, Everts M, Wang M, Kawakami Y, Waehler R, Mathews Q L, Yamamoto M, Rocconi R P, Siegal G P, Richter D F, Dall P, Zhu Z B, Curiel D T. Gene Transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system.  Cancer Biology Therapy. 2005;  4 11
    PubMedGoogle Scholar
  • 40 Dmitriev I, Krasnykh V, Miller C R, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel D T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.  J Virol. 1998;  72 9706-9713
    PubMedGoogle Scholar
  • 41 Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli R R, Vogt L, Ruedl C, Bachmann M F, Greber U F, Hemmi S. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3.  J Virol. 2004;  78 4454-4462
    CrossrefPubMedGoogle Scholar
  • 42 Short J J, Pereboev A V, Kawakami Y, Vasu C, Holterman M J, Curiel D T. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors.  Virology. 2004;  322 349-359
    CrossrefPubMedGoogle Scholar
  • 43 Stoff-Khalili M A, Rivera A A, Glasgow J N, Le L P, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz G J, Mathis J M, Pereboeva L, Seigal G P, Dall P, Curiel D T. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.  Gene Ther. 2005;  12 1696-1706
    CrossrefPubMedGoogle Scholar
  • 44 Gromeier M, Lachmann S, Rosenfeld M R, Gutin P H, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma.  Proc Natl Acad Sci USA. 2000;  97 6803-6808
    CrossrefPubMedGoogle Scholar
  • 45 Gromeier M, Wimmer E. Viruses for the treatment of malignant glioma.  Curr Opin Mol Ther. 2001;  3 503-508
    PubMedGoogle Scholar
  • 46 Merrill M K, Bernhardt G, Sampson J H, Wikstrand C J, Bigner D D, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma.  Neuro Oncol. 2004;  6 208-217
    PubMedGoogle Scholar
  • 47 Ochiai H, Moore S A, Archer G E, Okamura T, Chewning T A, Marks J R, Sampson J H, Gromeier M. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.  Clin Cancer Res. 2004;  10 4831-4838
    PubMedGoogle Scholar
  • 48 Kelm J M, Timmins N E, Brown C J, Fussenegger M, Nielsen L K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types.  Biotechnol Bioeng. 2003;  83 173-180
    PubMedGoogle Scholar
  • 49 Le L P, Everts M, Dmitriev I P, Davydova J G, Yamamoto M, Curiel D T. Fluorescently labeled adenovirus with pIX-EGFP for vector detection.  Mol Imaging. 2004;  3 105-116
    CrossrefPubMedGoogle Scholar
  • 50 Krumdieck C. A new instrument for the rapid preparation of tissue slices.  Anal Biochem. 1980;  104 118-123
    CrossrefPubMedGoogle Scholar
  • 51 Kirby T O, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras J L, Krumdieck C, Yamamoto M, Rots M G, Haisma H J, Alvarez R D, Mahasreshti P J, Curiel D T. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.  Clin Cancer Res. 2004;  10 8697-8703
    PubMedGoogle Scholar
  • 52 Bischoff J R, Kirn D H, Williams A, Heise C, Horn S, Muna M, Ng L, Nye J A, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p 53-deficient human tumor cells.  Science. 1996;  274 373-376
    CrossrefPubMedGoogle Scholar
  • 53 Vasey P A, Shulman L N, Campos S, Davis J, Gore M, Johnston S, Kirn D H, O'Neill V, Siddiqui N, Seiden M V, Kaye S B. Phase I trial of intraperitoneal injection of the E1B‐55-kd-gene-deleted adenovirus ONYX‐015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.  J Clin Oncol. 2002;  20 1562-1569
    CrossrefPubMedGoogle Scholar
  • 54 Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials.  Cancer Gene Ther. 2002;  9 979-986
    CrossrefPubMedGoogle Scholar
  • 55 Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial.  Gene Ther. 2001;  8 1618-1626
    CrossrefPubMedGoogle Scholar
  • 56 Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D. Selective replication and oncolysis in p 53 mutant tumors with ONYX‐015, an E1B‐55 kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial.  Cancer Res. 2000;  60 6359-6366
    PubMedGoogle Scholar
  • 57 Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?.  Gene Ther. 2001;  8 89-98
    CrossrefPubMedGoogle Scholar
  • 58 Reid T, Galanis E, Abbruzzese J, Sze D, Wein L M, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.  Cancer Res. 2002;  62 6070-6079
    PubMedGoogle Scholar
  • 59 Khuri F R, Nemunaitis J, Ganly I, Arseneau J, Tannock I F, Romel L, Gore M, Ironside J, MacDougall R H, Heise C, Randlev B, Gillenwater A M, Bruso P, Kaye S B, Hong W K, Kirn D H. A controlled trial of intratumoral ONYX‐015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.  Nat Med. 2000;  6 879-885
    CrossrefPubMedGoogle Scholar
  • 60 Wu H, Han T, Lam J T, Leath C A, Dmitriev I, Kashentseva E, Barnes M N, Alvarez R D, Curiel D T. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.  Gene Ther. 2004;  11 874-878
    CrossrefPubMedGoogle Scholar
  • 61 Heise C C, Williams A, Olesch J, Kirn D H. Efficacy of a replication-competent adenovirus (ONYX‐015) following intratumoral injection: Intratumoral spread and distribution effects.  Cancer Gene Ther. 1999;  6 499-504
    CrossrefPubMedGoogle Scholar
  • 62 Toda M, Rabkin S D, Martuza R L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.  Hum Gene Ther. 1998;  9 2177-2185
    PubMedGoogle Scholar
  • 63 Herrlinger U, Kramm C M, Aboody-Guterman K S, Silver J S, Ikeda K, Johnston K M, Pechan P A, Barth R F, Finkelstein D, Chiocca E A, Louis D N, Breakefield X O. Pre-existing herpes simplex virus 1 (HSV‐1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV‐1 vector.  Gene Ther. 1998;  5 809-819
    CrossrefPubMedGoogle Scholar
  • 64 Ganly I, Kirn D, Eckhardt G, Rodriguez G I, Soutar D S, Otto R, Robertson A G, Park O, Gulley M L, Heise C, Von Hoff D D, Kaye S B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.  Clin Cancer Res. 2000;  6 798-806
    PubMedGoogle Scholar
  • 65 Rogulski K R, Freytag S O, Zhang K, Gilbert J D, Paielli D L, Kim J H, Heise C C, Kirn D H. In vivo antitumor activity of ONYX‐015 is influenced by p 53 status and is augmented by radiotherapy.  Cancer Res. 2000;  60 1193-1196
    PubMedGoogle Scholar
  • 66 Breasted J. The Edwin Smith Surgical Papyrus. Chicago; University of Chicago Press 1930: 403-406
    Google Scholar
  • 67 de Moulin D. Historical notes on breast cancer, with emphasis on the Netherlands; III. The growth of scientific surgery in the 19th century.  Neth J Surg. 1982;  34 193-200
    PubMedGoogle Scholar
  • 68 Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi O P, Wilfond B, Borg A, Trent J. Gene-expression profiles in hereditary breast cancer.  N Engl J Med. 2001;  344 539-548
    CrossrefPubMedGoogle Scholar
  • 69 Schmutzler C, Vogel W. An interdisciplinary approach to breast and PCA. International Symposium: Breast and PCA: Genes, Hormones and the Environment, Garmisch-Partenkirchen, Germany, 22 - 24 April 1999.  Trends Endocrinol Metab. 2000;  11 115-116
    PubMedGoogle Scholar
  • 70 Dumitrescu R G, Cotarla I. Understanding breast cancer risk - where do we stand in 2005?.  J Cell Mol Med. 2005;  9 208-221
    PubMedGoogle Scholar
  • 71 Hulka B S, Moorman P G. Breast cancer: Hormones and other risk factors.  Maturitas. 2001;  38 103-113 113-106 (discussion)
    CrossrefPubMedGoogle Scholar
  • 72 Levi F, Randimbison L, Te V C, La Vecchia C. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast.  Int J Cancer. 2005;  116 820-823
    CrossrefPubMedGoogle Scholar
  • 73 Mc Pike H B. et al . Oral contraceptive use and early abortion risk as factors for breast cancer in young women.  Br J Cancer. 1981;  43 72-76
    PubMedGoogle Scholar
  • 74 Henderson I C. What can a woman do about her risk of dying of breast cancer?.  Curr Probl Cancer. 1990;  14 161-230
    PubMedGoogle Scholar
  • 75 Dupont W D, Page D L. Risk factors for breast cancer in women with proliferative breast disease.  N Engl J Med. 1985;  312 146-151
    CrossrefPubMedGoogle Scholar
  • 76 Kelsey J L, Gammon M D. The epidemiology of breast cancer.  CA Cancer J Clin. 1991;  41 146-165
    PubMedGoogle Scholar
  • 77 Harris J R, Lippman M E, Veronesi U, Willett W. Breast cancer (1).  N Engl J Med. 1992;  327 319-328
    PubMedGoogle Scholar
  • 78 Harris J R, Lippman M E, Veronesi U, Willett W. Breast cancer (2).  N Engl J Med. 1992;  327 390-398
    PubMedGoogle Scholar
  • 79 Harris J R, Lippman M E, Veronesi U, Willett W. Breast cancer (3).  N Engl J Med. 1992;  327 473-480
    PubMedGoogle Scholar
  • 80 Bodian C A. Benign breast diseases, carcinoma in situ, and breast cancer risk.  Epidemiol Rev. 1993;  15 177-187
    PubMedGoogle Scholar
  • 81 Grady D, Rubin S M, Petitti D B, Fox C S, Black D, Ettinger B, Ernster V L, Cummings S R. Hormone therapy to prevent disease and prolong life in postmenopausal women.  Ann Intern Med. 1992;  117 1016-1037
    PubMedGoogle Scholar
  • 82 zur Hausen H. Cervical carcinoma and human papillomavirus: On the road to preventing a major human cancer.  J Natl Cancer Inst. 2001;  93 252-253
    CrossrefPubMedGoogle Scholar
  • 83 Stuver S O, Boschi-Pinto C, Trichopoulos D. Infection with hepatitis B and C viruses, social class and cancer.  IARC Sci Publ. 1997;  138 319-324
    PubMedGoogle Scholar
  • 84 Bangham C R. HTLV‐1 infections.  J Clin Pathol. 2000;  53 581-586
    CrossrefPubMedGoogle Scholar
  • 85 Bittner J. Some possible effects of nursing on the mammary gland tumor incidence in mice.  Science (Wash DC). 1936;  84 162
    PubMedGoogle Scholar
  • 86 Callahan R, Smith G H. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.  Oncogene. 2000;  19 992-1001
    CrossrefPubMedGoogle Scholar
  • 87 Kordon E C, Smith G H. An entire functional mammary gland may comprise the progeny from a single cell.  Development. 1998;  125 1921-1930
    PubMedGoogle Scholar
  • 88 Pogo B G, Holland J F. Possibilities of a viral etiology for human breast cancer. A review.  Biol Trace Elem Res. 1997;  56 131-142
    PubMedGoogle Scholar
  • 89 Seifarth W, Skladny H, Krieg-Schneider F, Reichert A, Hehlmann R, Leib-Mosch C. Retrovirus-like particles released from the human breast cancer cell line T47-D display type B‐and C-related endogenous retroviral sequences.  J Virol. 1995;  69 6408-6416
    PubMedGoogle Scholar
  • 90 Dion A S, Girardi A J, Williams C C, Pomenti A A, Redfield E S. Responses of serum from breast cancer patients to murine mammary tumor virus: Fact or artifact?.  J Natl Cancer Inst. 1987;  79 207-211
    PubMedGoogle Scholar
  • 91 Kovarik A, Hlubinova K, Prachar J, Simkovic D, Knotek J. No significant correlation between specific antibodies to mouse mammary tumour virus and human cancer.  Br J Cancer. 1989;  60 572-575
    PubMedGoogle Scholar
  • 92 Wang Y, Holland J F, Bleiweiss I J, Melana S, Liu X, Pelisson I, Cantarella A, Stellrecht K, Mani S, Pogo B G. Detection of mammary tumor virus env gene-like sequences in human breast cancer.  Cancer Res. 1995;  55 5173-5179
    PubMedGoogle Scholar
  • 93 Wang Y, Pelisson I, Melana S M, Holland J F, Pogo B G. Detection of MMTV-like LTR and LTR‐env gene sequences in human breast cancer.  Int J Oncol. 2001;  18 1041-1044
    PubMedGoogle Scholar
  • 94 Wang Y, Pelisson I, Melana S M, Go V, Holland J F, Pogo B G. MMTV-like env gene sequences in human breast cancer.  Arch Virol. 2001;  146 171-180
    CrossrefPubMedGoogle Scholar
  • 95 Etkind P R, Stewart A F, Dorai T, Purcell D J, Wiernik P H. Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both the breast tumors and non-Hodgkin's lymphomas of individual patients diagnosed with both malignancies.  Clin Cancer Res. 2004;  10 5656-5664
    PubMedGoogle Scholar
  • 96 Etkind P, Du J, Khan A, Pillitteri J, Wiernik P H. Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient.  Clin Cancer Res. 2000;  6 1273-1278
    PubMedGoogle Scholar
  • 97 Wang Y, Melana S M, Baker B, Bleiweiss I, Fernandez-Cobo M, Mandeli J F, Holland J F, Pogo B G. High prevalence of MMTV-like env gene sequences in gestational breast cancer.  Med Oncol. 2003;  20 233-236
    PubMedGoogle Scholar
  • 98 Pogo B G, Melana S M, Holland J F, Mandeli J F, Pilotti S, Casalini P, Menard S. Sequences homologous to the mouse mammary tumor virus env gene in human breast carcinoma correlate with overexpression of laminin receptor.  Clin Cancer Res. 1999;  5 2108-2111
    PubMedGoogle Scholar
  • 99 Yin H, Medstrand P, Andersson M L, Borg A, Olsson H, Blomberg J. Transcription of human endogenous retroviral sequences related to mouse mammary tumor virus in human breast and placenta: Similar pattern in most malignant and nonmalignant breast tissues.  AIDS Res Hum Retroviruses. 1997;  13 507-516
    PubMedGoogle Scholar
  • 100 Stewart T H, Sage R D, Stewart A F, Cameron D W. Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus.  Br J Cancer. 2000;  82 446-451
    CrossrefPubMedGoogle Scholar
  • 101 Melana S M, Holland J F, Pogo B G. Search for mouse mammary tumor virus-like env sequences in cancer and normal breast from the same individuals.  Clin Cancer Res. 2001;  7 283-284
    PubMedGoogle Scholar
  • 102 Friedman L S, Ostermeyer E A, Lynch E D, Szabo C I, Meza J E, Anderson L A, Dowd P, Lee M K, Rowell S E. et al . 22 genes from chromosome 17q21: Cloning, sequencing, and characterization of mutations in breast cancer families and tumors.  Genomics. 1995;  25 256-263
    CrossrefPubMedGoogle Scholar
  • 103 Chan K H, Tam J S, Peiris J S, Seto W H, Ng M H. Epstein-Barr virus (EBV) infection in infancy.  J Clin Virol. 2001;  21 57-62
    CrossrefPubMedGoogle Scholar
  • 104 Sasco A J, Lowenfels A B, Pasker-de Jong P. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors.  Int J Cancer. 1993;  53 538-549
    CrossrefPubMedGoogle Scholar
  • 105 Schouten J T, Weese J L, Carbone P P. Lymphoma of the breast.  Ann Surg. 1981;  194 749-753
    PubMedGoogle Scholar
  • 106 Abhyankar S H, Chiang K Y, McGuirk J P, Pati A R, Godder K T, Welsh J A, Waldron R L, McElveen J L, Henslee-Downey P J. Late onset Epstein-Barr virus-associated lymphoproliferative disease after allogeneic bone marrow transplant presenting as breast masses.  Bone Marrow Transplant. 1998;  21 295-297
    CrossrefPubMedGoogle Scholar
  • 107 Yasui Y, Potter J D, Stanford J L, Rossing M A, Winget M D, Bronner M, Daling J. Breast cancer risk and “delayed” primary Epstein-Barr virus infection.  Cancer Epidemiol Biomarkers Prev. 2001;  10 9-16
    PubMedGoogle Scholar
  • 108 Gaffey M J, Frierson Jr H F, Mills S E, Boyd J C, Zarbo R J, Simpson J F, Gross L K, Weiss L M. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance.  Mod Pathol. 1993;  6 721-728
    PubMedGoogle Scholar
  • 109 Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, Heimann R. Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction.  Am J Clin Pathol. 1995;  103 449-452
    PubMedGoogle Scholar
  • 110 Weiss R A. Viruses and human cancer. Bio Scientific Publishers 2000: 1-15
    Google Scholar
  • 111 Liu B, Wang Y, Melana S M, Pelisson I, Najfeld V, Holland J F, Pogo B G. Identification of a proviral structure in human breast cancer.  Cancer Res. 2001;  61 1754-1759
    PubMedGoogle Scholar
  • 112 Levine P H, Pogo B G, Klouj A, Coronel S, Woodson K, Melana S M, Mourali N, Holland J F. Increasing evidence for a human breast carcinoma virus with geographic differences.  Cancer. 2004;  101 721-726
    CrossrefPubMedGoogle Scholar
  • 113 Ford C E, Tran D, Deng Y, Ta V T, Rawlinson W D, Lawson J S. Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women.  Clin Cancer Res. 2003;  9 1118-1120
    PubMedGoogle Scholar
  • 114 Melana S M. MMTV-like Particles in Human Breast Cancer. Cold Spring Harbor; Laboratory Annual Meeting on Retroviruses 2004: 178
    Google Scholar
  • 115 Stewart T, Tsai S C, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation.  Lancet. 1995;  346 796-798
    CrossrefPubMedGoogle Scholar
  • 116 Frisch M, Biggar R J, Engels E A, Goedert J J. Association of cancer with AIDS-related immunosuppression in adults.  Jama. 2001;  285 1736-1745
    CrossrefPubMedGoogle Scholar
  • 117 Lawson J S, Tran D, Rawlinson W D. From Bittner to Barr: A viral, diet and hormone breast cancer aetiology hypothesis.  Breast Cancer Res. 2001;  3 81-85
    CrossrefPubMedGoogle Scholar

Dr. med. Mariam A. Stoff-Khalili

Gene Therapy Center
University of Alabama at Birmingham

901, 19th Street South

BMR2 502, Birmingham

AL 35 294, USA

Email: mstoff@uab.edu